Molecular diagnosis of tuberculosis: the need for new diagnostic tools

The resurgence of tuberculosis over the past decade is now a familiar story to readers of Thorax. The interaction between HIV and mycobacteria is one of the significant causes. The consequences of this interaction have been well described and have served to exacerbate the problem of confirming a diagnosis of tuberculosis.

Throughout the developing world the majority of adults are infected with *Mycobacterium tuberculosis* which has led to tuberculosis being seen as one of the commonest secondary diseases associated with HIV in these societies. In contrast, disease due to *Mycobacterium avium* is rarely seen, which has allowed sputum microscopy to retain its specificity as a diagnostic tool.

Unlike many of the organisms that afflict the HIV seropositive patient, *M. tuberculosis* is a virulent pathogen and therefore causes disease in those with minimal immunosuppression who are infected with HIV. These patients present with features indistinguishable from those seen before the HIV era. As immunosuppression deepens, tuberculosis becomes an increasingly disseminated disease and provokes a less brisk immune response. Cavitation becomes rarer, lesions are less confined to the apices, and extrapulmonary disease becomes more common. A consequence of these changes is that fewer patients have positive sputum smears on direct microscopy, which accords with the smaller numbers of bacilli found in sputum from HIV seropositive patients. HIV-related immunosuppression also leads to an increased susceptibility to disease following recent infection or reinfection. This may also explain the increase in numbers of cases with disease reminiscent of primary infection with pleural effusions, hilar lymphadenopathy and miliary spread, most of whom have negative sputum microscopy.

In Lusaka, the capital city of Zambia, for instance, 75% of tuberculosis patients are HIV seropositive. In 1993 more than one third of pretreatment samples that grew *M. tuberculosis* were negative on direct smear (G Kahenya, Chest Disease Laboratory, Lusaka, Annual Report 1993) and only 19% of new cases were smear positive (R Mssika, National AIDS, STD, TB and Leprosy Control Programme, Annual Report 1993), although the latter statistic may also reflect poor utilisation of the microscopy services.

From a theoretical viewpoint the rise in smear negative disease does not alter the approach to tuberculosis control. The goal must still be to find smear positive cases and treat them effectively. However, it is clear that the large number of patients with tuberculosis but negative sputum smears will be a huge stress on the diagnostic and clinical services in countries where both epidemics overlap, and a new diagnostic tool that is more rapid than culture and more sensitive than microscopy, but still specific, would be a major advance.

In contrast, in the industrialised world mycobacterial disease in those infected with HIV is more frequently due to *M. avium*, particularly in those with advanced immunosuppression, and the priority here is the individual patient rather than the community. In addition to the need for rapid diagnosis in the paucibacillary case, there is also a real need to distinguish between different acid fast bacilli and traditional methods involving cultivation may take weeks.

**Approaches through molecular genetics**

Although mycobacteria raise technical and safety issues when brought into laboratories, the recent advances that have been made in mycobacterial molecular genetics have led to better understanding of pathogenesis and epidemiology, as well as to possibilities for diagnosis and avenues to explore for vaccine development.

In the diagnostic field detection of nucleic acids, either directly by hybridisation to a labelled probe or following amplification of specific sequences of DNA or RNA, raises the exciting possibility of a sensitive specific diagnosis that would provide an answer within hours rather than days or weeks.

As particular genes are cloned and sequenced, It becomes possible to select target sequences that are specific to species in the *M. tuberculosis* complex. Such sequences have been used as probes to try to detect small amounts of tuberculosis DNA in clinical material. Sadly, the sensitivity has been disappointing and the only commercial probe to be released was withdrawn when it was realised that it was little better than microscopy, despite considerably more effort and expense.

**Molecular amplification techniques**

The description of the polymerase chain reaction (PCR) using a thermostable DNA polymerase to amplify DNA exponentially by simply cycling the temperature of the reaction has led to a flurry of activity to produce diagnostic tests for tuberculosis. In principle, the exquisite sensitivity of PCR, combined with the inherent specificity of the target DNA sequence, makes it an attractive option. The first paper to describe PCR as a diagnostic test for tuberculosis appeared in 1989, and since then there have been over 60 similar publications attesting to the perceived importance of new diagnostic tools, but also highlighting the difficulties experienced in taking the technique from the research bench into the routine laboratory. Nor is PCR the only amplification technique being developed with commercial backers. Ligase chain reaction (LCR), transcription mediated amplification (TMA) (Gen-probe “Amplified M tuberculosis Direct”), and strand displacement amplification (SDA) are all capable of exponential amplification of nucleic acids from a specific target, either by cycling the temperature (PCR, LCR) or by the dynamics of specific enzymes at a constant temperature (TMA, SDA). The limiting steps are likely to be similar for all these techniques – namely, how to prevent contamination of reactions with the products of previous assays and how best to extract the mycobacterial nucleic acids.
by these advantages the reaction to ensure product reduces the amplified mixture in theoretically, single internal primers can only re-amplify the product which has already been detected, preventing false positives.26 However, whereas the different products can be detected by agarose gel electrophoresis, colorimetric detection methods suitable for use with ELISA plate readers cannot distinguish different sized products.25 Furthermore, the modified “control” target may compete with the real target leading to lower sensitivity.26

Despite a few small studies that found positive PCRs in patients with asymptomatic tuberculous infection, or previous fully treated disease,29 30 a consensus is now emerging from the thousands of specimens that have been tested.21 27 30 31 It seems that PCR can indeed detect DNA from clinical samples containing M tuberculosis within a day. Sputum has been the starting point for most of these assays, although a recent study reported that M tuberculosis-specific nucleic acids could also be amplified from the blood of eight patients with smear positive pulmonary tuberculosis.32 The sensitivity of most assays is similar to that of culture and the specificity is also high if appropriate care and controls are used. However, direct comparisons with routine mycobacterial culture are of limited value since it is generally accepted that a proportion of patients with “genuine” tuberculosis will have negative cultures. PCR also remains positive for longer than either microscopy or culture once a patient starts treatment,33 although more studies are needed to quantify this more accurately. Prospectively designed studies that include close follow up of patients for at least six months after specimens are submitted are needed to define the gold standard against which PCR results should be compared to calculate sensitivity and specificity. Furthermore, these comparisons must be performed in a blinded fashion; it will always be hard to avoid bias when “discrepancy resolution” is undertaken.17

The newer amplification techniques, particularly TMA, will reach a similar consensus more rapidly as the trials will be larger and better designed with the experience of PCR to emulate. The challenges for the commercial companies taking these tests into the market place will be to develop closed lysis systems that do not require repeated opening of reaction vessels, and methods to detect the amplified product that do not require the tube to be opened again. However, it must be borne in mind that no test has so far proved to be much more sensitive than culture, and that the use of Bactec (Becton Dickinson) radiopsiometric culture with probes commercially available from Gen-probe may give a culture result in only a week.

Future prospects
New methods of diagnosis will inevitably become most available in the parts of the world with least tuberculosis. The emphasis here will be on benefits for the individual patient and resource allocation will be a relatively minor concern. It is also in these environments that new tests will be most challenged. In the setting of low disease prevalence, an extremely high specificity will be required
Molecular diagnosis of tuberculosis

To prevent most of the reported positive results being false positives.

In the parts of the world where tuberculosis is still killing millions and control programmes are swamped by the rising tide of HIV-related disease, the role of any new techniques will have to be compared very critically with sputum microscopy which is already capable of detecting those cases most at risk of continuing to spread the epidemic. Nonetheless, the clinical officer is still faced with many symptomatic people with negative sputum smears for whom he must decide how best to care. Many of the obstacles to using molecular amplification techniques in these situations are being overcome. The reagent cost of the single tube nested PCR test is less than that of a sheet of x ray film. The suggestion that PCR will be oversensitive and detect those with latent tuberculosis infection or treated tuberculosis is not borne out by work in Zambia or Tanzania. The “high technology” of amplification techniques should be no more of an impediment than the introduction of ELISA technology which is now widespread in much of the world.

Molecular diagnosis of tuberculosis will never replace microscopy as the foundation of tuberculosis control, but health facilities sophisticated enough to produce chest radiographs should follow developments in molecular diagnosis closely.

The ZAMBART molecular laboratory is funded by grants from the Science and Technology for Developing Countries programme of the Commission of the European Communities and the Tuberculosis Unit of the World Health Organisation. PG-F is a Beit Memorial Medical Fellow.

ZAMBART Project, Department of Medicine, University Teaching Hospital, PO Box 50110, Lusaka, Zambia

P GODFREY-FAUSETT


Downloaded from http://thorax.bmj.com/ on June 23, 2017 - Published by group.bmj.com
Molecular diagnosis of tuberculosis: the need for new diagnostic tools.

P Godfrey-Faussett

Thorax 1995 50: 709-711
doi: 10.1136/thx.50.7.709

Updated information and services can be found at:
http://thorax.bmj.com/content/50/7/709.citation

These include:
Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/